GlassScriptPhysician profile
Clifford Brooks
NPI 1255454021
$3,349.34
in general payments reported to CMS, 2019-2025
29 companies · $657 in 2025
The $657 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $352 · 2020: $60.05 · 2021: $222 · 2022: $433 · 2023: $838 · 2024: $787 · 2025: $657.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,143 · Education: $139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,143.37 |
| Education | $138.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $502.24 | 2019-2025 | Eylea Hd, Eylea |
| Sight Sciences, INC. | $328.85 | 2021-2025 | Omni Surgical System, Sion Surgical Instrument |
| Amgen INC. | $273.34 | 2024-2025 | Tepezza |
| Horizon Therapeutics Plc | $246.56 | 2021-2023 | Tepezza |
| Genentech USA, INC. | $206.66 | 2022-2025 | Vabysmo |
| Abbvie INC. | $182.69 | 2022-2025 | Lumigan, Vuity |
| Alcon Vision LLC | $173.73 | 2021-2025 | Rocklatan, Clareon, Centurion |
| Mallinckrodt Hospital Products INC. | $168.80 | 2022-2023 | Acthar |
| Astellas Pharma Global Development | $158.75 | 2024 | Izervay |
| Novartis Pharmaceuticals Corporation | $148.09 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $113.35 | 2025 | Xdemvy |
| Allergan, INC. | $97.39 | 2019-2022 | |
| Harrow Eye, LLC | $96.78 | 2024-2025 | Triesence, Iheezo |
| Johnson & Johnson Vision Care, INC. | $93.49 | 2019-2025 | |
| Apellis Pharmaceuticals, INC. | $87.82 | 2022-2025 | Syfovre |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $79.01 | 2019-2022 | |
| Biotissue Holdings INC. | $56.59 | 2019-2025 | |
| Aerie Pharmaceuticals, INC. | $52.66 | 2019-2021 | |
| Dompe US, INC. | $47.68 | 2024-2025 | Oxervate |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $38.91 | 2019-2021 | |
| Astellas Pharma US INC | $38.60 | 2023-2025 | Izervay |
| Ani Pharmaceuticals, INC. | $27.54 | 2024 | Purified Cortrophin Gel |
| Oyster Point Pharma, INC. | $24.24 | 2023 | Tyrvaya |
| Glaukos Corporation | $24.07 | 2023 | |
| Shire North American Group INC | $21.28 | 2019 | |
| Sun Pharmaceutical Industries INC. | $18.32 | 2019 | |
| Bausch & Lomb Americas INC. | $14.74 | 2024 | Vyzulta |
| Ivantis, INC | $13.84 | 2021 | |
| Rxsight INC | $13.32 | 2024 | Light Adjustable Lens (Lal), Rxsight Contact Lens, Rxsight Injector Cartridge |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clifford Brooks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.